Cat. No.: HY-113556

Sappanone A

8 Cited Publications

Avis client

Based on 8 publication(s) in Google Scholar

Sappanone A is an orally active homoisoflavone found in sappan L. Sappanone A is a PDE4 and NF-κB inhibitor with anti-inflammatory and antioxidant effect. Sappanone A induces HO-1 expression through activation of Nrf2 pathway. Sappanone A also inhibits RANKL-induced osteoclastogenesis. Sappanone A has great potential in the research of inflammation-related and cardiovascular .

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.87%
CAS No.: 102067-84-5
Formule: C₁₆H₁₂O₅
Masse moléculaire:284.26

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Sappanone A Chemical Structure

CAS No.: 102067-84-5

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (8)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform Phosphodiesterase (PDE) :

Voir tous les produits spécifiques à Isoform NF-κB :

Voir tous les produits spécifiques à Isoform TNF Receptor :

Voir tous les produits spécifiques à Isoform Akt :

Voir tous les produits spécifiques à Isoform ERK :

Voir tous les produits spécifiques à Isoform p38 MAPK :

Voir tous les produits spécifiques à Isoform NO Synthase :

Voir tous les produits spécifiques à Isoform Interleukin Related :

Voir tous les produits spécifiques à Isoform COX :

Voir tous les produits spécifiques à Isoform JNK :

Cellular Effect

Cell Line	Type	Value	Description	References
RAW264.7	IC₅₀	5.7 μM Compound: 7	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide generation incubated for 24 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide generation incubated for 24 hrs	[PMID: 23234407]
RAW264.7	IC₅₀	8.3 μM Compound: 7	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production incubated for 24 hrs by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production incubated for 24 hrs by ELISA	[PMID: 23234407]
RAW264.7	IC₅₀	9.3 μM Compound: Sappanone A	Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS stimulation for 24 hrs by Griess assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS stimulation for 24 hrs by Griess assay	[PMID: 28038832]

In Vitro

Sappanone A (5-30 μM, pretreatment for 1 h, then 24 h) inhibits LPS-induced NO, IL-6 and PGE 2 production in RAW264.7 cells in a concentration-dependent manner (IC₅₀ 6.8, 11.2 and 12.6 μM, respectively) without cytotoxicity^[1].
Sappanone A (5-30 μM, 24 h) exerts anti-inflammatory effects in RAW264.7 cells by inducing HO-1 expression and inhibits LPS-induced NF-κB activation through activation of Nrf2^[2].
Sappanone A (10-40 μM) remarkably inhibits PDE4 enzyme activity and reduces TNF-α production induced by LPS in RAW264.7 macrophages^[2].
Sappanone A (0.007-1.0 mM, 40 min) has excellent ability to reduce Fe³⁺ and complex Fe²⁺, shows excellent antioxidant activity^[2].
Sappanone A (3-30 μM, 7 days) inhibits RANKL-induced osteoclastogenesis in mouse bone marrow-derived macrophage (BMM)^[3].
Sappanone A (0-30 μM, 7 days) inhibits RANKL-induced NFATc1 activation and AKT phosphorylation in BMMs^[3].
Sappanone A (10-30 μM, pretreatment for 1 hour, then treatment for 24 hours) blocks the NF-κB pathway and inhibits the inflammatory response in the HG-induced mesangial cell model^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[1]

Cell Line:

RAW264.7cells
Concentration:

5, 15, 30 μM
Incubation Time:

24 h
Result:

Reduced the mRNA levels of iNOS, COX-2, and IL-6 in a concentration-dependent manner.
Increased HO-1 mRNA expression level in a concentration-dependent manner, and HO-1 mRNA increased 3 hours after treatment, peaked at 6 hours, and returned to basal levels at 24 hours.
Induced HO-1 expression by activating Nrf2, resulting in a concentration-dependent increase in the mRNA levels of NQO1 and GCLC.

Western Blot Analysis^[3]

Cell Line:

BMM cells
Concentration:

0, 3, 10, 30 μM
Incubation Time:

7 days
Result:

Increased the phosphorylation levels of ERK, p38 and JNK mitogen-activated protein kinases (MAPKs) in a time-dependent manner and pretreatment.
Inhibited RANKL-induced NFATc1 expression.

In Vivo

Sappanone A (20, 50 mg/kg, i.p., one dose) protects mice from death in the LPS-induced mortality in C57BL/6 mice model^[1].
Sappanone A (50, 100 mg/kg, i.p., twice a day for seven consecutive days) significantly reduces LPS-induced mice acute lung injury (ALI) without obvious toxic side effects^[2].
Sappanone A (50 mg/kg, i.p., injects every other day for a total of eight days) inhibits osteoclast formation in vivo in the LPS-induced mouse bone loss model^[3].
Sappanone A (20 mg/kg, i.p., one dose) can reduce myocardial necrosis and apoptosis and promote the recovery of cardiac function in the myocardial ischemia reperfusion injury (MIRI) rat model^[4].
Sappanone A (10-30 mg/kg, i.g., once a day for twelve weeks) reduces renal injury during hyperglycemia in a dose-dependent manner in a Streptozotocin (HY-13753)-induced diabetic mouse model^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

ALI in Institute of Cancer Research mice (male 20-25 g) was established by intratracheal instillation of 0.5 mg/kg LPS in 100 μl saline solution.^[2]
Dosage:

50,100 mg/kg
Administration:

i.p., twice a day for seven consecutive days, 1 h prior to LPS injection
Result:

Significantly reduced the production of TNF-α in lung tissue, protein content in BALF, and MPO activity.
Had a good effect on the growth, development and behavior of mice, and no death or obvious toxic side were observed.

Animal Model:

Institute of Cancer Research mice (male 6 weeks) injected with LPS (5 mg/kg)^[3]
Dosage:

50 mg/kg
Administration:

i.p., injected every other day for a total of eight days
Result:

LPS-induced significant decreased in the number of TRAP-positive osteoclasts.
Had a good effect on the growth, development and behavior of mice, and no death or obvious toxic side were observed.

Animal Model:

Wistar rats (male 250 g) MIRI model (hearts were isolated and underwent 30-min ischemia, followed by 120-min reperfusion)^[4]
Dosage:

20 mg/kg
Administration:

i.p., one dose, 1 h prior to heart isolation
Result:

Reduce myocardial ischemia-reperfusion injury and myocardial infarction area.
Significantly improved LVDP and ±dp/dt values at 30, 60, and 120 min of reperfusion, indicating that it promoted the recovery of cardiac function after ischemia-reperfusion.
Inhibited ischemia-reperfusion-induced cardiomyocyte apoptosis by reducing cell apoptosis and inhibited the expression of cleaved caspase-3.
Significantly reduced the content of ROS and MDA in ischemic myocardium, and increased the activity of SOD and GSH-Px in ischemic myocardium.
Downregulated the expression of Keap1, decreased the level of Nrf2 in the cytoplasm, and increased the level of Nrf2 in the nucleus, and also activated the transcriptional activity to upregulate the expression of Nrf2 target genes (HO-1 and NQO1).
Enhanced the phosphorylation of Nfr2 through the PKC or PI3K pathway.

Animal Model:

Streptozotocin (50 mg/kg, i.p., 5 consecutive days) induced diabetic C57BL/6J mice (20-23 g, 6-8 weeks)^[5]
Dosage:

10, 20, 30 mg/kg
Administration:

i.g., once a day for twelve consecutive weeks
Result:

Showed that the increase of serum creatinine and BUN was significantly attenuated, and the 24-hour urine protein of mice was significantly reduced.
Alleviated the pathological changes in Streptozotocin-treated mice, reduced the production of fibrotic molecules transforming growth factor β1 (TGF-β1) and collagen IV (Col-IV), and decreased the expression of inflammatory cytokines interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α).

Chemical Information

CAS No. 102067-84-5
Appearance Solid
Masse moléculaire 284.26
Formule C₁₆H₁₂O₅
Color Light yellow to yellow
SMILES

O=C1/C(COC2=CC(O)=CC=C12)=C/C3=CC=C(O)C(O)=C3
Structure Classification
- Flavonoids
- Isoflavones
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (8)

All Cell Proliferation/Viability AssayRT-PCRELISAHistological Imaging/StainingWB

Sort by:

Journal Impact Factor

Int J Biol Sci

Exploring the Mechanism of Ferroptosis Induction by Sappanone A in Cancer: Insights into the Mitochondrial Dysfunction Mediated by NRF2/xCT/GPX4 Axis. [Abstract]

2024 Sep 23;20(13):5145-5161. PMID: 39430236
Phytother Res

Sappanone A Exerted Strong Anti-Inflammatory Effects in the Treatment of Atopic Dermatitis Through IL-21R-Mediated JAK1/STAT3 Pathway. [Abstract]

2025 Nov 14. PMID: 41236101

Sappanone A purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Nov 14. [Abstract]

In vitro cell viabilities of HaCaT cells after incubation with different concentrations of Sappanone A (SA) (0, 5, 10, 20, 40, and 80 μM) for 72 h were measured by the CCK-8 assay.

Sappanone A purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Nov 14. [Abstract]

The relative mRNA expression of Th2-associated inflammatory cytokines was measured by RT-qPCR. HaCaT cells were treated with various concentrations of Sappanone A (SA) (10, 20, 40 μM) or left untreated under IL-4/IL-13/TNF-α stimulation.

Sappanone A purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Nov 14. [Abstract]

The protein levels of IL-1β, IL-25, IL-33, and TSLP were detected by ELISA assays. HaCaT cells were treated with various concentrations of Sappanone A (SA) (10, 20, 40 μM), DEX, or left untreated under IL-4/IL-13/TNF-α stimulation.

Sappanone A purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Nov 14. [Abstract]

Representative images of H&E staining CD4 staining, TB staining, and F4/80 staining in ear tissues treated with Sappanone A SA (10, 20 mg/kg).

Sappanone A purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Nov 14. [Abstract]

Western blotting assay showed the expression of key proteins in the IL-21R/JAK/STAT pathway in HaCaT cells Sappanone A SA (10, 20, 40 μM).
Int J Mol Sci

Hydrogen Mitigated Doxorubicin-Induced Liver Injury via Nrf2/HO-1 Pathway Activation. [Abstract]

2026 Mar 19;27(6):2774. PMID: 41898634
Int Immunopharmacol

Hydrogen alleviates cardiac ferroptosis damage under chronic intermittent hypoxia conditions by targeting Nrf2. [Abstract]

2025 Dec 9:169:115974. PMID: 41370977
Eur J Pharmacol

Sappanone A ameliorated imiquimod-induced psoriasis-like dermatitis in BALB/c mice via suppressing Mmp8 expression and IL-17 signaling pathway. [Abstract]

2024 Jun 14:176746. PMID: 38880219
Toxicol Appl Pharmacol

Sappanone A ameliorates acute lung injury through inhibiting the activation of the NF-κB signaling pathway. [Abstract]

2024 Nov:492:117127. PMID: 39419123
Naunyn Schmiedebergs Arch Pharmacol

Sappanone a alleviates osteoarthritis progression by inhibiting chondrocyte ferroptosis via activating the SIRT1/Nrf2 signaling pathway. [Abstract]

2024 Nov;397(11):8759-8770. PMID: 38832987
Pharmacological Research - Modern Chinese Medicine

2025 Jun.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (351.79 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5179 mL

17.5895 mL

35.1791 mL

5 mM

0.7036 mL

3.5179 mL

7.0358 mL

10 mM

0.3518 mL

1.7590 mL

3.5179 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (7.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (7.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (285 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Lee S, et, al. Sappanone A exhibits anti-inflammatory effects via modulation of Nrf2 and NF-κB. Int Immunopharmacol. 2015 Sep;28(1):328-36. [Content Brief]

[2]. Wang YZ, et al. Sappanone A: A natural PDE4 inhibitor with dual anti-inflammatory and antioxidant activities from the heartwood of Caesalpinia sappan L. J Ethnopharmacol. 2023 Mar 25;304:116020. [Content Brief]

[3]. Choo YY, et al. Sappanone A inhibits RANKL-induced osteoclastogenesis in BMMs and prevents inflammation-mediated bone loss. Int Immunopharmacol. 2017 Nov;52:230-237. [Content Brief]

[4]. Shi X, et al. Sappanone A Protects Against Myocardial Ischemia Reperfusion Injury by Modulation of Nrf2. Drug Des Devel Ther. 2020 Jan 8;14:61-71. [Content Brief]

[5]. Wang Z, et al. Sappanone a prevents diabetic kidney disease by inhibiting kidney inflammation and fibrosis via the NF-κB signaling pathway. Front Pharmacol. 2022 Aug 16;13:953004. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5179 mL	17.5895 mL	35.1791 mL	87.9477 mL
	5 mM	0.7036 mL	3.5179 mL	7.0358 mL	17.5895 mL
	10 mM	0.3518 mL	1.7590 mL	3.5179 mL	8.7948 mL
	15 mM	0.2345 mL	1.1726 mL	2.3453 mL	5.8632 mL
	20 mM	0.1759 mL	0.8795 mL	1.7590 mL	4.3974 mL
	25 mM	0.1407 mL	0.7036 mL	1.4072 mL	3.5179 mL
	30 mM	0.1173 mL	0.5863 mL	1.1726 mL	2.9316 mL
	40 mM	0.0879 mL	0.4397 mL	0.8795 mL	2.1987 mL
	50 mM	0.0704 mL	0.3518 mL	0.7036 mL	1.7590 mL
	60 mM	0.0586 mL	0.2932 mL	0.5863 mL	1.4658 mL
	80 mM	0.0440 mL	0.2199 mL	0.4397 mL	1.0993 mL
	100 mM	0.0352 mL	0.1759 mL	0.3518 mL	0.8795 mL

Sappanone A

8 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Sappanone A

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Flavonoids Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Sappanone A

Voir tous les produits spécifiques à Isoform Phosphodiesterase (PDE)

Voir tous les produits spécifiques à Isoform NF-κB

Voir tous les produits spécifiques à Isoform TNF Receptor

Voir tous les produits spécifiques à Isoform Akt